Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, 61 Colindale Avenue, London, UK.
Norwich Medical School, University of East Anglia, Norwich, UK.
J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345. doi: 10.1093/jac/dky363.
Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam. Disturbingly, mutations in KPC carbapenemases can confer ceftazidime/avibactam resistance, which is sometimes selected during therapy. We explored whether this risk extended to AmpC and ESBL enzymes.
Mutants were selected by plating AmpC-derepressed strains, ESBL producers and ceftazidime-susceptible controls on agar containing ceftazidime + avibactam (1 or 4 mg/L). MICs were determined by CLSI agar dilution; WGS was by Illumina methodology.
Using 2× MIC of ceftazidime + 1 mg/L avibactam, mutants were selected from all strain types at frequencies of 10-7-10-9. Rates diminished to <10-9 with 4 mg/L avibactam or higher MIC multiples, except with AmpC-derepressed Enterobacteriaceae. Characterized mutants (n = 10; MICs 4-64 mg/L) of AmpC-derepressed strains had modifications in ampC, variously giving Arg168Pro/His, Gly176Arg/Asp, Asn366Tyr or small deletions around positions 309-314. Mutants of ESBL producers (n = 19; MICs 0.5-16 mg/L) mostly had changes affecting permeability, efflux or β-lactamase quantity; only one had an altered β-lactamase, with an Asp182Tyr substitution in CTX-M-15, raising the ceftazidime/avibactam MIC, but abrogating other cephalosporin resistance. Mutants of ceftazidime-susceptible strains were not sequenced, but phenotypes suggested altered drug accumulation or, for Enterobacter cloacae only, AmpC derepression. In further experiments, avibactam reduced, but did not abolish, selection of AmpC-derepressed Enterobacteriaceae by ceftazidime.
Most mutants of AmpC-derepressed Enterobacteriaceae had structural mutations in ampC; those of ESBL producers mostly had genetic modifications outside β-lactamase genes, commonly affecting uptake, efflux, or β-lactamase quantity. The clinical significance of these observations remains to be determined.
越来越多的革兰氏阴性菌感染采用新的β-内酰胺酶抑制剂组合进行治疗,例如头孢他啶/阿维巴坦。令人不安的是,KPC 碳青霉烯酶的突变可导致头孢他啶/阿维巴坦耐药,而这种耐药性有时在治疗过程中被选择。我们探讨了这种风险是否扩展到 AmpC 和 ESBL 酶。
通过在含有头孢他啶+阿维巴坦(1 或 4mg/L)的琼脂平板上对去阻遏 AmpC 菌株、ESBL 产生菌和头孢他啶敏感对照物进行划线培养,选择突变体。通过 CLSI 琼脂稀释法测定 MIC;通过 Illumina 方法进行 WGS。
使用 2×MIC 的头孢他啶+1mg/L 阿维巴坦,除 AmpC 去阻遏肠杆菌科外,所有菌株类型的突变体选择频率均为 10-7-10-9。当使用 4mg/L 阿维巴坦或更高的 MIC 倍数时,频率降至<10-9,除非 MIC 为 4-64mg/L。特征化的突变体(n=10;MIC 为 4-64mg/L)去阻遏 AmpC 的菌株中,ampC 发生了修饰,分别为 Arg168Pro/His、Gly176Arg/Asp、Asn366Tyr 或 309-314 位附近的小缺失。ESBL 产生菌(n=19;MIC 为 0.5-16mg/L)的突变体大多发生了影响通透性、外排或β-内酰胺酶数量的变化;只有一个突变体改变了β-内酰胺酶,CTX-M-15 中的 Asp182Tyr 取代导致头孢他啶/阿维巴坦 MIC 升高,但消除了其他头孢菌素的耐药性。未对头孢他啶敏感菌株的突变体进行测序,但表型表明药物蓄积改变,或者仅大肠埃希菌的 AmpC 去阻遏。在进一步的实验中,阿维巴坦降低了但没有完全消除头孢他啶对去阻遏肠杆菌科的选择。
大多数去阻遏 AmpC 的肠杆菌科突变体的 ampC 发生了结构突变;ESBL 产生菌的突变体大多发生了β-内酰胺酶基因以外的基因修饰,通常影响摄取、外排或β-内酰胺酶数量。这些观察结果的临床意义仍有待确定。